+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Primary non-Hodgkin's lymphoma of the mandible treated with radiotherapy, chemotherapy, and autologous peripheral blood stem cell transplantation



Primary non-Hodgkin's lymphoma of the mandible treated with radiotherapy, chemotherapy, and autologous peripheral blood stem cell transplantation



Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 90(4): 450-455



Extranodal presentation in non-Hodgkin's lymphoma (NHL) is uncommon, and the mandible is very rarely involved. Primary NHL of the mandible, for the most part, has intermediate or high malignancy and has a much greater incidence of local recurrence compared with other sites of involvement. A 48-year-old Japanese man with NHL of the mandible received radiotherapy, followed by high-dose chemotherapy supported with peripheral blood stem cell transplantation (PBSCT). High-dose cyclophosphamide, Adriamycin, and vincristine were used for pretransplant conditioning. He achieved complete remission and has survived in continuous complete remission for more than 72 months to date. Marrow-ablative chemotherapy facilitated by PBSCT is thought to be useful as part of the primary therapy for patients with NHL who have poorer prognoses.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011198239

Download citation: RISBibTeXText

PMID: 11027381

DOI: 10.1067/moe.2000.108441


Related references

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(10): 1547-1555, 2000

High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Journal of Clinical Oncology 12(10): 2176-2186, 1994

Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. British Journal of Haematology 175(3): 440-447, 2016

Curative efficacy for nasal type extranodal NK/T-cell lymphoma by autologous peripheral blood stem cell transplantation after sequencing chemotherapy and radiotherapy. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21(6): 1477-1481, 2013

A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group. Japanese Journal of Clinical Hematology 40(10): 1058-1067, 1999

An Infant With Medulloepithelioma Successfully Treated by High-dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation Without Radiotherapy. Journal of Pediatric Hematology/Oncology 37(6): E394-E398, 2015

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106(4): 1473-1478, 2005

Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: A prospective randomised trial. European Journal of Cancer 37(14): 1781-1789, 2001

High-clore chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with malignant lymphoma--its role in the treatment strategy for non-Hodgkin's lymphoma, and ESHAP + PBSCT therapy. Japanese Journal of Clinical Hematology 37(7): 591-597, 1996

Non-Hodgkin's lymphoma: Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 30(2): 103-111, 2002

Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 113(23): 6011-6014, 2009

Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases. American Journal of Hematology 70(1): 60-63, 2002

A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 27(4): 433-436, 2001

Primary breast T-cell lymphoma, unspecified, treated with autologous peripheral blood stem cell transplantation: A case report and literature review. Oncology Letters 7(1): 156-158, 2014

Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bailliere's Best Practice and Research. Clinical Haematology 12(1-2): 151-169, 2000